Structure–activity relationship and in vitro inhibition of human cytochrome CYP2A6 and CYP2A13 by flavonoids

References

• Andarwulan N, Batari R, Sandrasari DA, et al. (2010). Flavonoid content and antioxidant activity of vegetables from Indonesia. Food Chem 121:1231–5.
   PubMed Web of Science ®Google Scholar
• Andarwulan N, Kurniasih D, Apriady RA, et al. (2012). Polyphenols, carotenoids, and ascorbic acid in underutilized medicinal vegetables. J Funct Foods 4:339–47.
   Web of Science ®Google Scholar
• Arct J, Pytkowska K. (2008). Flavonoids as components of biologically active cosmeceuticals. Clin Dermatol 26:347–57.
   PubMed Web of Science ®Google Scholar
• Boonruang S, Prakobsri K, Pouyfung P, et al. (2017). Inhibition of human cytochromes P450 2A6 and 2A13 by flavonoids, acetylenic thiophenes and sesquiterpene lactones from Pluchea indica and Vernonia cinerea. J Enzyme Inhib Med Chem 32:1136–42.
   PubMed Web of Science ®Google Scholar
• Chan WK, Nguyen LT, Miller VP, Harris RZ. (1998). Mechanism-based inactivation of human cytochrome P450 3A4 by grapefruit juice and red wine. Life Sci 62:PL135–PL142.
   PubMed Web of Science ®Google Scholar
• Chiang HC, Wang CY, Lee HL, Tsou TC. (2011). Metabolic effects of CYP2A6 and CYP2A13 on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced gene mutation — a mammalian cell-based mutagenesis approach. Toxicol Appl Pharmacol 253:145–52.
   PubMed Web of Science ®Google Scholar
• DeVore NM, Scott EE. (2012). Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone binding and access channel in human cytochrome P450 2A6 and 2A13 enzymes. J Biol Chem 287:26576–85.
   PubMed Web of Science ®Google Scholar
• Di YM, Chow VDW, Yang LP, Zhou SF. (2009). Structure, function, regulation and polymorphism of human cytochrome P450 2A6. Curr Drug Metab 10:754–80.
   PubMed Web of Science ®Google Scholar
• Doostdar H, Burke MD, Mayer RT. (2000). Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. Toxicology 144:31–8.
   PubMed Web of Science ®Google Scholar
• Havsteen BH. (2002). The biochemistry and medical significance of the flavonoids. Pharmacol Therapeut 96:67–202.
   PubMed Web of Science ®Google Scholar
• Hecht SS. (1998). Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem Res Toxicol 11:559–603.
   PubMed Web of Science ®Google Scholar
• Hecht SS. (1999). Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 91:1194–210.
   PubMed Web of Science ®Google Scholar
• Hecht SS. (2003). Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer 3:733–44.
   PubMed Web of Science ®Google Scholar
• Hodek P, Trefil P, Stiborová M. (2002). Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chem-Biol Interact 139:1–21.
   PubMed Web of Science ®Google Scholar
• Hukkanen J, Jacob P, Benowitz NL. (2005). Metabolism and disposition kinetics of nicotine. Pharmacol Rev 57:79–115.
   PubMed Web of Science ®Google Scholar
• Kakimoto K, Murayama N, Takenaka S, et al. (2019). Cytochrome P450 2A6 and other human P450 enzymes in the oxidation of flavone and flavanone. Xenobiotica 49:131–42.
   PubMed Web of Science ®Google Scholar
• Kale A, Gawande S, Kotwal S. (2008). Cancer phytotherapeutics: role for flavonoids at the cellular level. Phytother Res 22:567–77.
   PubMed Web of Science ®Google Scholar
• Kandagatla SK, Mack T, Simpson S, et al. (2014). Inhibition of human cytochrome P450 2E1 and 2A6 by aldehydes: structure and activity relationships. Chem-Biol Interact 219:195–202.
   PubMed Web of Science ®Google Scholar
• Khlebnikov AI, Schepetkin IA, Domina NG, et al. (2007). Improved quantitative structure–activity relationship models to predict antioxidant activity of flavonoids in chemical, enzymatic, and cellular systems. Bioorg Med Chem 15:1749–70.
   PubMed Web of Science ®Google Scholar
• Kimura Y, Ito H, Ohnishi R, Hatano T. (2010). Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9 activity. Food Chem Toxicol 48:429–35.
   PubMed Web of Science ®Google Scholar
• Koenigs LL, Peter RM, Thompson SJ, et al. (1997). Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. Drug Metab Dispos 25:1407–15.
   PubMed Web of Science ®Google Scholar
• Kramlinger VM, von Weymarn LB, Murphy SE. (2012). Inhibition and inactivation of cytochrome P450 2A6 and cytochrome P450 2A13 by menthofuran, β-nicotyrine and menthol. Chem-Biol Interact 197: 87–92.
   PubMed Web of Science ®Google Scholar
• Kubota T, Nakajima-Taniguchi C, Fukuda T, et al. (2006). CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation. Pharmacogenomics J 6:115.
   PubMed Web of Science ®Google Scholar
• Lautraite S, Musonda AC, Doehmer J, et al. (2002). Flavonoids inhibit genetic toxicity produced by carcinogens in cells expressing CYP1A2 and CYP1A1. Mutagenesis 17:45–53.
   PubMed Web of Science ®Google Scholar
• Li Y, Wang E, Patten CJ, et al. (1994). Effects of flavonoids on cytochrome P450-dependent acetaminophen metabolism in rats and human liver microsomes. Drug Metab Dispos 22:566–71.
   PubMed Web of Science ®Google Scholar
• Maenpuen S, Sopitthummakhun K, Yuthavong Y, et al. (2009). Characterization of plasmodium falciparum serine hydroxymethyltransferase-A potential antimalarial target. Mol Biochem Parasit 168:63–73.
   PubMed Web of Science ®Google Scholar
• Malaiyandi V, Sellers EM, Tyndale RF. (2005). Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin Pharmacol Ther 77:145–58.
   PubMed Web of Science ®Google Scholar
• Megaraj V, Zhou X, Xie F, et al. (2014). Role of CYP2A13 in the bioactivation and lung tumorigenicity of the tobacco-specific lung procarcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone: in vivo studies using a CYP2A13-humanized mouse model. Carcinogenesis 35:131–7.
   PubMed Web of Science ®Google Scholar
• Moon YJ, Wang X, Morris ME. (2006). Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol In Vitro 20:187–210.
   PubMed Web of Science ®Google Scholar
• Oscarson M. (2001). Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism. Drug Metab Dispos 29:91–5.
   PubMed Web of Science ®Google Scholar
• Otake Y, Walle T. (2002). Oxidation of the flavonoids galangin and kaempferide by human liver microsomes and CYP1A1, CYP1A2, and CYP2C9. Drug Metab Dispos 30:103–5.
   PubMed Web of Science ®Google Scholar
• Peto R, Boreham J, Lopez AD, et al. (1992). Mortality from tobacco in developed countries: indirect estimation from national vital statistics. Lancet 339: 1268–78.
   PubMed Web of Science ®Google Scholar
• Pianezza ML, Sellers EM, Tyndale RF. (1998). Nicotine metabolism defect reduces smoking. Nature 393:750.
   PubMed Web of Science ®Google Scholar
• Pouyfung P, Prasopthum A, Sarapusit S, et al. (2014). Mechanism-based inactivation of cytochrome P450 2A6 and 2A13 by Rhinacanthus nasutus constituents. Drug Metab Pharmacokinet 29:75–82.
   PubMed Web of Science ®Google Scholar
• Prasopthum A, Pouyfung P, Sarapusit S, et al. (2015). Inhibition effects of Vernonia cinerea active compounds against cytochrome P450 2A6 and human monoamine oxidases, possible targets for reduction of tobacco dependence. Drug Metab Pharmacokinet 30:174–81.
   PubMed Web of Science ®Google Scholar
• Schwab GE, Raucy JL, Johnson EF. (1988). Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by alpha-naphthoflavone. Mol Pharmacol 33:493–9.
   PubMed Web of Science ®Google Scholar
• Seyoum A, Asres K, El-Fiky FK. (2006). Structure–radical scavenging activity relationships of flavonoids. Phytochemistry 67:2058–70.
   PubMed Web of Science ®Google Scholar
• Shimada T. (2017). Inhibition of carcinogen-activating cytochrome P450 enzymes by xenobiotic chemicals in relation to antimutagenicity and anti-carcinogenicity. Toxicol Res 33:79–96.
   PubMed Web of Science ®Google Scholar
• Shimada T, Kim D, Murayama N, et al. (2013). Binding of diverse environmental chemicals with human cytochromes P450 2A13, 2A6, and 1B1 and enzyme inhibition. Chem Res Toxicol 26:517–28.
   PubMed Web of Science ®Google Scholar
• Shimada T, Murayama N, Kakimoto K, et al. (2018). Oxidation of 1-chloropyrene by human CYP1 family and CYP2A subfamily cytochrome P450 enzymes: catalytic roles of two CYP1B1 and five CYP2A13 allelic variants. Xenobiotica 48:565–75.
   PubMed Web of Science ®Google Scholar
• Shimada T, Tanaka K, Takenaka S, et al. (2010). Structure-function relationships of inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2C9, and 3A4 by 33 flavonoid derivatives. Chem Res Toxicol 23:1921–35.
   PubMed Web of Science ®Google Scholar
• Smith BD, Sanders JL, Porubsky PR, et al. (2007). Structure of the human lung cytochrome P450 2A13. J Biol Chem 282:17306–13.
   PubMed Web of Science ®Google Scholar
• Su T, Bao Z, Zhang QY, et al. (2000). Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res 60:5074–9.
   PubMed Web of Science ®Google Scholar
• Suriyaphan O. (2014). Nutrition, health benefits and applications of Pluchea indica (L.) Less leaves. Pharm Sci Asia 41:1–10.
   Google Scholar
• Tsujimoto M, Horie M, Honda H, et al. (2009). The structure–activity correlation on the inhibitory effects of flavonoids on cytochrome P450 3A activity. Biol Pharm Bull 32:671–6.
   PubMed Web of Science ®Google Scholar
• Walle T. (2007). Methoxylated flavones, a superior cancer chemopreventive flavonoid subclass?. Semin Cancer Biol 17:354–62.
   PubMed Web of Science ®Google Scholar
• Walle T, Ta N, Kawamori T, et al. (2007). Cancer chemopreventive properties of orally bioavailable flavonoids—methylated versus unmethylated flavones. Biochem Pharmacol 73:1288–96.
   PubMed Web of Science ®Google Scholar
• Walle UK, Walle T. (2007). Bioavailable flavonoids: cytochrome P450-mediated metabolism of methoxyflavones. Drug Metab Dispos 35:1985–9.
   PubMed Web of Science ®Google Scholar
• World Health Organization. (2017). WHO report on the global tobacco epidemic, 2017: monitoring tobacco use and prevention policies. Geneva, Switzerland: World Health Organization.
   Google Scholar
• Xi Z, Spiller K, Gardner EL. (2009). Mechanism-based medication development for the treatment of nicotine dependence. Acta Pharmacol Sin 30:723–39.
   PubMed Web of Science ®Google Scholar
• Yano JK, Denton TT, Cerny MA, et al. (2006). Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization. J Med Chem 49:6987–7001.
   PubMed Web of Science ®Google Scholar
• Zhai S, Dai R, Wei X, et al. (1998). Inhibition of methoxyresorufin demethylase activity by flavonoids in human liver microsomes. Life Sci 63:PL119–PL123.
   PubMed Web of Science ®Google Scholar
• Zhang S, Yang X, Coburn RA, Morris ME. (2005). Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein. Biochem Pharmacol 70:627–39.
   PubMed Web of Science ®Google Scholar